Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242094 | 0.85 | ALDH1A1 (0.63) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8235814 | 0.84 | ALDH1A1 (0.55) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8242756 | 0.84 | ALDH1A1 (0.74) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL14518102 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8241638 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8243107 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8241967 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8241629 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL8235186 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HTTKDM4ECDK8CDK19 | |
| SCHEMBL6101444 | 0.78 | KDM4E (0.78) | ALDH1A1HTTKDM4ECDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931683-B1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7767815-B2 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767815-B2 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-7687501-B2 | Pyridothienopyridazinone derivatives as mGluR1 antagonists | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687501-B2 | Pyridothienopyridazinone derivatives as mGluR1 antagonists | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| WO-2007032854-A1 | FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007024593-A1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | ALDH1A1 1119/4885HTT 501/4885KDM4E 2200/4885 |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | ALDH1A1 1121/4885HTT 339/4885KDM4E 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.